Dr John Craig Williamson, EDD | |
11724 Seward Hwy, Suite E, Seward, AK 99664-9708 | |
(907) 362-1804 | |
Not Available |
Full Name | Dr John Craig Williamson |
---|---|
Gender | Male |
Speciality | Psychologist - Counseling |
Location | 11724 Seward Hwy, Seward, Alaska |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1124295589 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TC1900X | Psychologist - Counseling | 470 (Alaska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr John Craig Williamson, EDD Po Box 2732, Seward, AK 99664-2732 Ph: (907) 224-2476 | Dr John Craig Williamson, EDD 11724 Seward Hwy, Suite E, Seward, AK 99664-9708 Ph: (907) 362-1804 |
News Archive
UnitedHealth Group Inc. (UNH), the biggest U.S. health insurer, increased its 2012 earnings forecast after reporting that first-quarter profit beat analysts' estimates for higher enrollment and low medical costs. ... UnitedHealth's shares climbed, along with other health insurers, after Chief Executive Officer Stephen Hemsley said he expects only a "gradual" rise in health spending this year.
Until December, 2011, UNC Health Care System relied upon a legacy Human Resources system that was not designed for the healthcare industry. And this mismatch created problems that necessitated awkward, albeit creative, workarounds. But now, thanks to CIBER partnering with UNC to implement the Lawson Human Capital Management (HCM) solution, they are responsive and agile, especially in terms of reporting and employee issues.
Comprehensive Care Corporation today announced the launching of its behavioral health services for a health plan in Texas.
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").
World leaders on Tuesday "pledged to take wide-ranging action to prevent millions of deaths from cancer, diabetes, and heart and lung disease by tackling the key causes - smoking, excessive drinking, lack of exercise and unhealthy diets dominated by fast food," but the "declaration approved at the first-ever General Assembly meeting on chronic diseases which ended Tuesday left unanswered the question of coordinating an international response to what the leaders called 'a challenge of epidemic proportions,'" the Associated Press/CBS News reports.
› Verified 7 days ago